Aethlon Medical Discusses Potential to Treat Patients Co-Infected With Both HIV/AIDS and Hepatitis C.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that its Hemopurifier(TM) treatment technology has demonstrated multi-pathogen clearance capabilities that could lead to a simultaneous treatment for persons infected with both HIV and the Hepatitis C virus (HCV). The Hemopurifier is a medical device that converges the use of hollow-fiber dialysis technology with affinity chromatography to separate and selectively capture viruses and toxins from the blood. Recent enhancements to the Hemopurifier include the immobilization of a single affinity agent that is able to attach to the surface of both HIV and HCV.

Aethlon CEO James A. Joyce stated, "Our studies provide compelling evidence that the Hemopurifier is able to simultaneously capture both HIV and HCV from the blood of infected patients." Joyce continued, "To date, an effective method to concurrently treat both diseases has yet to evolve."

According to the Centers for Disease Control and Prevention, about one quarter of HIV-infected persons in the United States are also infected with HCV. HCV is one of the most important causes of chronic liver disease in the United States and HCV infection progresses more rapidly to liver damage in HIV-infected persons. HCV infection also impacts the ability to manage HIV infection. As previously indicated, Aethlon is targeting the HIV-Hemopurifier to be a conjunction therapy to enhance and prolong established HIV drug regimens, and to serve as a treatment option for drug resistant HIV patients. An HCV-Hemopurifier is being developed for treatment resistant HCV patients.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.